JP2011529942A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011529942A5 JP2011529942A5 JP2011521561A JP2011521561A JP2011529942A5 JP 2011529942 A5 JP2011529942 A5 JP 2011529942A5 JP 2011521561 A JP2011521561 A JP 2011521561A JP 2011521561 A JP2011521561 A JP 2011521561A JP 2011529942 A5 JP2011529942 A5 JP 2011529942A5
- Authority
- JP
- Japan
- Prior art keywords
- crystalline form
- compound
- formula
- methylbenzenesulfonate
- xrpd
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0814340.6 | 2008-08-05 | ||
| GBGB0814340.6A GB0814340D0 (en) | 2008-08-05 | 2008-08-05 | Anhydrous crystol form fo a pyridine derivative |
| PCT/EP2009/060089 WO2010015626A1 (en) | 2008-08-05 | 2009-08-04 | Crystalline forms of a pyridine derivative |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011529942A JP2011529942A (ja) | 2011-12-15 |
| JP2011529942A5 true JP2011529942A5 (enExample) | 2012-09-27 |
Family
ID=39767571
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011521561A Withdrawn JP2011529942A (ja) | 2008-08-05 | 2009-08-04 | ピリジン誘導体の結晶体 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8093242B2 (enExample) |
| EP (1) | EP2321324A1 (enExample) |
| JP (1) | JP2011529942A (enExample) |
| KR (1) | KR20110052686A (enExample) |
| CN (1) | CN102171219A (enExample) |
| AU (1) | AU2009279135B2 (enExample) |
| BR (1) | BRPI0917224A2 (enExample) |
| CA (1) | CA2733235A1 (enExample) |
| EA (1) | EA201170300A1 (enExample) |
| GB (1) | GB0814340D0 (enExample) |
| IL (1) | IL210777A0 (enExample) |
| MX (1) | MX2011001414A (enExample) |
| WO (1) | WO2010015626A1 (enExample) |
| ZA (1) | ZA201100426B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010288502B2 (en) * | 2009-08-27 | 2013-12-12 | KaNDy Therapeutics Ltd. | Anhydrate forms of a pyridine derivative |
| HUE047732T2 (hu) * | 2015-05-18 | 2020-05-28 | Nerre Therapeutics Ltd | NK-1/NK-3 receptor antagonista vértolulások kezeléséhez |
| PL3765024T3 (pl) | 2018-03-14 | 2024-08-05 | KaNDy Therapeutics Limited | <div>Nowa formulacja farmaceutyczna zawierająca podwójnych antagonistów receptora nk-1/nk-3</div> |
| JP7673064B2 (ja) | 2019-11-15 | 2025-05-08 | カンディー セラピューティクス リミテッド | Ｎｔ－８１４の重要な中間体である６－クロロ－４－（４－フルオロ－２－メチルフェニル）ピリジン－３－アミンを作製するための新規な化学的方法 |
| WO2025242585A1 (en) | 2024-05-24 | 2025-11-27 | Bayer Consumer Care Ag | Crystalline forms of salts of elinzanetant and compositions containing salts of elinzanetant |
| WO2025242583A1 (en) | 2024-05-24 | 2025-11-27 | Bayer Consumer Care Ag | Novel formulation comprising elinzanetant in a solid dispersion |
| US12533358B1 (en) | 2025-05-14 | 2026-01-27 | Bayer Consumer Care Ag | Methods of treatment with elinzanetant |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6274604B1 (en) | 1996-07-17 | 2001-08-14 | Merck & Co., Inc. | Alteration of circadian rhythmicity with a tachykinin antagonist |
| DK1394150T3 (da) * | 1999-02-24 | 2011-03-21 | Hoffmann La Roche | 4-phenylpyridinderivater og deres anvendelse som NK-1-receptorantagonister |
| WO2001030348A1 (en) | 1999-10-25 | 2001-05-03 | Janssen Pharmaceutica N.V. | Use of substance p antagonists for influencing the circadian timing system |
| GB0203022D0 (en) | 2002-02-08 | 2002-03-27 | Glaxo Group Ltd | Chemical compounds |
| GB0203020D0 (en) | 2002-02-08 | 2002-03-27 | Glaxo Group Ltd | Chemical compounds |
| TW200403058A (en) * | 2002-04-19 | 2004-03-01 | Bristol Myers Squibb Co | Heterocyclo inhibitors of potassium channel function |
| HRP20070471T3 (hr) * | 2003-07-03 | 2007-11-30 | F. Hoffmann - La Roche Ag | Dvojni nk1/nk3 antagonisti za liječenje shizofrenije |
| US7683056B2 (en) * | 2005-09-09 | 2010-03-23 | Glaxosmithkline Llc | Pyridine derivatives and their use in the treatment of psychotic disorders |
-
2008
- 2008-08-05 GB GBGB0814340.6A patent/GB0814340D0/en not_active Ceased
-
2009
- 2009-08-04 EA EA201170300A patent/EA201170300A1/ru unknown
- 2009-08-04 WO PCT/EP2009/060089 patent/WO2010015626A1/en not_active Ceased
- 2009-08-04 BR BRPI0917224A patent/BRPI0917224A2/pt not_active IP Right Cessation
- 2009-08-04 US US13/056,775 patent/US8093242B2/en active Active
- 2009-08-04 MX MX2011001414A patent/MX2011001414A/es unknown
- 2009-08-04 JP JP2011521561A patent/JP2011529942A/ja not_active Withdrawn
- 2009-08-04 CN CN2009801393221A patent/CN102171219A/zh active Pending
- 2009-08-04 AU AU2009279135A patent/AU2009279135B2/en not_active Ceased
- 2009-08-04 EP EP09781468A patent/EP2321324A1/en not_active Withdrawn
- 2009-08-04 CA CA2733235A patent/CA2733235A1/en not_active Abandoned
- 2009-08-04 KR KR1020117005159A patent/KR20110052686A/ko not_active Withdrawn
-
2011
- 2011-01-17 ZA ZA2011/00426A patent/ZA201100426B/en unknown
- 2011-01-20 IL IL210777A patent/IL210777A0/en unknown